Amedeo Smart

Free Medical Literature Service



Alzheimer's Disease

  Free Subscription

Articles published in
    March 2023
    Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
    BMJ. 2023;380:p628.
    >> Share

    January 2023
    Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.
    BMJ. 2023;380:p73.
    >> Share

    Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report.
    BMJ. 2023;380:p6.
    >> Share

    December 2022
  4. WALSH S, Merrick R, Richard E, Nurock S, et al
    Lecanemab for Alzheimer's disease.
    BMJ. 2022;379:o3010.
    >> Share

    August 2022
  5. DYER O
    Alzheimer's: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease.
    BMJ. 2022;378:o2041.
    >> Share

    April 2022
  6. DHANA K, Franco OH, Ritz EM, Ford CN, et al
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ. 2022;377:e068390.
    >> Share

    March 2022
  7. DYER O
    Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
    BMJ. 2022;376:o808.
    >> Share

    January 2022
  8. LYTHGOE MP, Jenei K, Prasad V
    Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    BMJ. 2022;376:e069780.
    >> Share

    December 2021
    Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
    BMJ. 2021;375:n3127.
    >> Share

    November 2021
  10. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    >> Share

    September 2021
  11. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    >> Share

    August 2021
  12. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    >> Share

    July 2021
  13. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    >> Share

  14. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    >> Share

    June 2021
  15. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    >> Share

  16. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    >> Share

    February 2021
  17. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    >> Share

    October 2020
  18. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016